Pharma Deals Review, Vol 2006, No 68 (2006)

Font Size:  Small  Medium  Large

Pfizer Secures Rights to Exubera® from Sanofi-Aventis

Business Review Editor

Abstract


Pfizer and Sanofi-Aventis entered into license agreement to acquire worldwide rights to Exubera® (human insulin [rDNA orgin]) inhalation powder for treating diabetes. The deal could be worth up to US$1.3 B to Sanofi-Aventis.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.